Literature DB >> 19408994

Radiosurgery for angiographically occult vascular malformations.

Martin Pham1, Bradley A Gross, Bernard R Bendok, Issam A Awad, H Hunt Batjer.   

Abstract

The use of radiosurgery for angiographically occult vascular malformations (AOVMs) is a controversial treatment option for those that are surgically inaccessible or located in eloquent brain. To determine the efficacy of this treatment, the authors reviewed the literature reporting hemorrhage rates, seizure control, and radiation-induced morbidity. They found overall hemorrhage rates of 2-6.4%, overall postradiosurgery hemorrhage rates of 1.6-8%, and stratified postradiosurgery hemorrhage rates of 7.3-22.4% in the period immediately to 2 years after treatment; these latter rates declined to 0.8-5.2% > 2 years after treatment. Of 291 patients presenting with seizure across 16 studies, 89 (31%) attained a seizure-free status and 102 (35%) had a reduction in seizure frequency after radiosurgery. Overall radiation-induced morbidity ranged from 2.5 to 59%, with higher complication rates in patients with brainstem lesion locations. Researchers applying mean radiation doses of 15-16.2 Gy to the tumor margin saw both low radiation-induced complication rates (0-9.1%) and adequate hemorrhage control (0.8-5.2% > 2 years after treatment), whereas mean doses >or= 16.5 Gy were associated with higher total radiation-induced morbidity rates (> 17%). Although the use of stereotactic radiosurgery remains controversial, patients with AOVMs located in surgically inaccessible areas of the brain may benefit from such treatment.

Entities:  

Mesh:

Year:  2009        PMID: 19408994     DOI: 10.3171/2009.2.FOCUS0923

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  9 in total

Review 1.  Cavernous malformations: natural history, diagnosis and treatment.

Authors:  Sachin Batra; Doris Lin; Pablo F Recinos; Jun Zhang; Daniele Rigamonti
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

Review 2.  Rho kinase as a target for cerebral vascular disorders.

Authors:  Lisa M Bond; James R Sellers; Lisa McKerracher
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

Review 3.  Cerebral cavernous malformations: from molecular pathogenesis to genetic counselling and clinical management.

Authors:  Remco A Haasdijk; Caroline Cheng; Anneke J Maat-Kievit; Henricus J Duckers
Journal:  Eur J Hum Genet       Date:  2011-08-10       Impact factor: 4.246

4.  Diagnosis and treatment of vascular malformations of the brain.

Authors:  Bradley A Gross; Rose Du
Journal:  Curr Treat Options Neurol       Date:  2014-01       Impact factor: 3.598

5.  Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH).

Authors:  Sean P Polster; Ying Cao; Timothy Carroll; Kelly Flemming; Romuald Girard; Daniel Hanley; Nicholas Hobson; Helen Kim; James Koenig; Janne Koskimäki; Karen Lane; Jennifer J Majersik; Nichol McBee; Leslie Morrison; Robert Shenkar; Agnieszka Stadnik; Richard E Thompson; Joseph Zabramski; Hussein A Zeineddine; Issam A Awad
Journal:  Neurosurgery       Date:  2019-04-01       Impact factor: 4.654

Review 6.  Tailored Treatment Options for Cerebral Cavernous Malformations.

Authors:  Jessa E Hoffman; Blake Wittenberg; Brent Morel; Zach Folzenlogen; David Case; Christopher Roark; Samy Youssef; Joshua Seinfeld
Journal:  J Pers Med       Date:  2022-05-20

Review 7.  Pediatric cerebral cavernous malformations: Genetics, pathogenesis, and management.

Authors:  Michael G Z Ghali; Visish M Srinivasan; Arvind C Mohan; Jeremy Y Jones; Peter T Kan; Sandi Lam
Journal:  Surg Neurol Int       Date:  2016-12-28

Review 8.  Brainstem Cavernous Malformations Management: Microsurgery vs. Radiosurgery, a Meta-Analysis.

Authors:  George Fotakopoulos; Hugo Andrade-Barazarte; Juri Kivelev; Mardjono Tjahjadi; Felix Goehre; Juha Hernesniemi
Journal:  Front Surg       Date:  2022-01-10

9.  Outcome of intracerebral cavernoma treated by Gamma Knife radiosurgery based on a double-blind assessment of treatment indication.

Authors:  Chiung-Chyi Shen; Meei-Ling Sheu; Ming Hsi Sun; Meng-Yin Yang; Weir-Chiang You; Yen-Ju Chen; Ying Ju Chen; Jason Sheehan; Hung-Chuan Pan
Journal:  Radiat Oncol       Date:  2021-08-28       Impact factor: 3.481

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.